Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT

Abstract Candidates for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) frequently have “mismatch” lesions with pronounced 18-fluorodeoxyglucose ([18F]FDG) but attenuated PSMA ligand uptake on positron emission t...

Full description

Bibliographic Details
Published in:Scientific Reports
Main Authors: Florian Rosar, Caroline Burgard, Scott David, Robert J. Marlowe, Mark Bartholomä, Stephan Maus, Sven Petto, Fadi Khreish, Andrea Schaefer-Schuler, Samer Ezziddin
Format: Article
Language:English
Published: Nature Portfolio 2024-05-01
Subjects:
mCRPC
PSMA
FDG
Mismatch
Radioligand therapy
Online Access:https://doi.org/10.1038/s41598-024-61961-z

Internet

https://doi.org/10.1038/s41598-024-61961-z

Similar Items